Bangkok Dusit Medical Services Investment Budget Update

Goldman Sachs maintains a Buy rating on BDMS following the company's decision to increase its investment budget for the WellEra wellness project to Bt29b. While the firm lowered its target price slightly to Bt28.2, it views the expansion as a long-term strategic opportunity to drive growth via medical tourism and wellness services.

Key Takeaways

• 1.BDMS announced a 23% increase in the WellEra project investment budget from Bt23.5b to Bt29b.
• 2.The firm maintains a Buy rating but lowers the target price to Bt28.2 due to increased Capex requirements.
• 3.The project is expected to be completed in 2030, with management expecting a negligible earnings impact through 2028.

Table of Contents

• What happened?
• GS Views
• Price Target, Risks, and Methodology - Bangkok Dusit Medical Services
• Investment Thesis - Bangkok Dusit Medical Services
• Disclosure Appendix

Document Preview

Page 1 of 5

Subscribe for full accessStart Free Trial